The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Stroke prevention in atrial fibrillation: Past, present and future: Comparing the guidelines and practical decision-making
Abstract
Summary: Concepts and our approaches to stroke prevention in atrial fibrillation (AF) have changed markedly over the last decade. There has been an evolution over the approach to stroke and bleeding risk assessment, as well as new treatment options. An increasing awareness of AF has led to calls to improve the detection of and population screening for AF. Stroke and bleeding risk assessment continues to evolve, and the ongoing debate on balance between simplicity and practicality, against precision medicine will continue. In this review article, we provide an overview of past, present and the (likely) future concepts and approaches to stroke prevention in AF. We propose three simple steps (the Birmingham ‘3-step’) that offers a practical management pathway to help streamline and simplify decision-making for stroke prevention in patients with AF. Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citationRuff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · cited 1×
“The NOACs have changed how we approach stroke prevention in AF, as they offer relative efficacy, safety and convenience compared to VKAs, in patients with AF, with an overall clear net clinical benefit (46, 47).”
BackgroundHart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793 · cited 2×
“The historical randomised controlled trials (RCTs) comparing warfarin to placebo or control, conducted two decades ago, clearly showed that warfarin reduced stroke/systemic embolism by 64 % and all-cause mortality by 26 % (5, 6).”
BackgroundPisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
Self-citation2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Self-citationIdarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,167
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Milling, T. J., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Gold, A., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607887 · Cited by 807
Independent predictors of stroke in patients with atrial fibrillation: A systematic review
The Stroke Risk in Atrial Fibrillation Working Group (2007) · Neurology · doi:10.1212/01.wnl.0000267275.68538.8d · Cited by 547
Man-Son-Hing, M., Nichol, G., Lau, A., & Laupacis, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.7.677 · Cited by 538
Hijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lopes, R. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00741-8 · Cited by 490
Apostolakis, S., Sullivan, R. M., Olshansky, B., & Lip, G. Y. H. (2013) · Chest · doi:10.1378/chest.13-0054 · Cited by 482
Self-citationVerma, A., Cairns, J. A., Mitchell, L. B., Macle, L., Stiell, I. G., Gladstone, D., McMurtry, M. S., Connolly, S., Cox, J. L., Dorian, P., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.08.001 · Cited by 477
Stroke prevention in atrial fibrillation
Freedman, B., Potpara, T. S., & Lip, G. Y. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31257-0 · Cited by 463
Self-citationLarsen, T. B., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Lip, G. Y. H. (2016) · BMJ · doi:10.1136/bmj.i3189 · Cited by 441
Self-citationHijazi, Z., Lindbäck, J., Alexander, J. H., Hanna, M., Held, C., Hylek, E. M., Lopes, R. D., Oldgren, J., Siegbahn, A., Stewart, R. A. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw054 · Cited by 437
Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013): – Digest Version –
JCS Joint Working Group (2014) · Circulation Journal · doi:10.1253/circj.cj-66-0092 · Cited by 427
Hendriks, J. M. L., de Wit, R., Crijns, H. J. G. M., Vrijhoef, H. J. M., Prins, M. H., Pisters, R., Pison, L. A. F. G., Blaauw, Y., & Tieleman, R. G. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs071 · Cited by 409
Hughes, M., Lip, G. Y. H., & on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-08-0508 · Cited by 371
Self-citationHusted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Huber, K., Jespersen, J., Kristensen, S. D., Lip, G. Y. H., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0443 · Cited by 365
Self-citationHusted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Huber, K., Jespersen, J., Kristensen, S., Lip, G. Y. H., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0403 · Cited by 364
Self-citationDonal, E., Lip, G. Y. H., Galderisi, M., Goette, A., Shah, D., Marwan, M., Lederlin, M., Mondillo, S., Edvardsen, T., Sitges, M., et al. (2016) · European Heart Journal – Cardiovascular Imaging · doi:10.1093/ehjci/jev354 · Cited by 341
Self-citationScreening to identify unknown atrial fibrillation: A systematic review
Lowres, N., Neubeck, L., Redfern, J., & Freedman, S. B. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0165 · Cited by 327
Melgaard, L., Gorst-Rasmussen, A., Lane, D. A., Rasmussen, L. H., Larsen, T. B., & Lip, G. Y. H. (2015) · JAMA · doi:10.1001/jama.2015.10725 · Cited by 315
Self-citationGraham, D. J., Reichman, M. E., Wernecke, M., Hsueh, Y.-H., Izem, R., Southworth, M. R., Wei, Y., Liao, J., Goulding, M. R., Mott, K., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.5954 · Cited by 312
(1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.12.1316 · Cited by 302
Macle, L., Cairns, J., Leblanc, K., Tsang, T., Skanes, A., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 272
Friberg, L., Benson, L., Rosenqvist, M., & Lip, G. Y. H. (2012) · BMJ · doi:10.1136/bmj.e3522 · Cited by 268
Self-citationGuidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013):– Digest Version –
JCSJointWorkingGroup (2014) · Circulation · Cited by 262
Keshishian, A., Kamble, S., Pan, X., Mardekian, J., Horblyuk, R., Hamilton, M., & Lip, G. Y. H. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0403 · Cited by 262
Self-citationCauses of Death and Influencing Factors in Patients with Atrial Fibrillation
Fauchier, L., Villejoubert, O., Clementy, N., Bernard, A., Pierre, B., Angoulvant, D., Ivanes, F., Babuty, D., & Lip, G. Y. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.045 · Cited by 180
Self-citationRaparelli, V., Proietti, M., Cangemi, R., Lip, G. Y. H., Lane, D. A., & Basili, S. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0757 · Cited by 180
Self-citationWagstaff, A. J., Overvad, T. F., Lip, G. Y. H., & Lane, D. A. (2014) · QJM · doi:10.1093/qjmed/hcu054 · Cited by 176 · cited 1×
“The Sc (Sex category) criterion refers to female sex, which older literature suggested increased stroke risk (19), but it became apparent there was an agedependency to this risk, such that females aged <65 in the absence of any additional stroke risk factors were at low risk (with stroke rates of <1 %/year) (20).”
BackgroundSelf-citationAdjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00018 · Cited by 173
Katholing, A., Wallenhorst, C., Freedman, S. B., & Martinez, C. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-04-0350 · Cited by 173
What is ‘valvular’ atrial fibrillation? A reappraisal
De Caterina, R., & Camm, A. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu352 · Cited by 164
Self-citationReilly, P. A., Bernstein, R. A., Dubiel, R., Eikelboom, J. W., Glund, S., Huisman, M. V., Hylek, E. M., Kam, C. W., Kamphuisen, P. W., Kreuzer, J., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0192 · Cited by 164
Hippisley‐Cox, J., Coupland, C. A. C., & Brindle, P. M. (2013) · BMJ · doi:10.1136/bmj.f2573 · Cited by 163
Kirchhof, P. F., BREITHARDT, G. E., Bax, J. J., Benninger, G., Blomström‐Lundqvist, C., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H. G., et al. (2015) · EP Europace · doi:10.1093/europace/euv304 · Cited by 162
Self-citationReversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 161
Friberg, L., Benson, L., & Lip, G. Y. H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu139 · Cited by 161
Self-citationPisters, R., Lane, D. A., Marin, F., Camm, A. J., & Lip, G. Y. H. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-1036 · Cited by 159
Self-citationHecker, J., Marten, S., Keller, L., Helmert, S., Michalski, F., Werth, S., Sahin, K., Tittl, L., & Beyer-Westendorf, J. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-10-0840 · Cited by 159
Lip, G. Y. H., Lane, D. A., van Walraven, C., & Hart, R. G. (2006) · Stroke · doi:10.1161/01.str.0000236840.00467.84 · Cited by 155
Self-citationAtrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease
Lau, Y. C., Proietti, M., Guiducci, E., Blann, A. D., & Lip, G. Y. H. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.057 · Cited by 150
Self-citationLip, G. Y. H., Clémenty, N., Pericart, L., Banerjee, A., & Fauchier, L. (2014) · Stroke · doi:10.1161/strokeaha.114.007199 · Cited by 148
Self-citationThe CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?
Eikelboom, J. W., & Karthikeyan, G. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0757 · Cited by 146
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation
Ebertz, F., Förster, K., Gelbricht, V., Michalski, F., Köhler, C. U., Werth, S., Endig, H., Pannach, S., Tittl, L., Şahin, K., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0954 · Cited by 139
Senoo, K., Proietti, M., Lane, D. A., & Lip, G. Y. H. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.001 · Cited by 128
Self-citationWide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation
Quinn, G. R., Severdija, O. N., Chang, Y., & Singer, D. E. (2016) · Circulation · doi:10.1161/circulationaha.116.024057 · Cited by 128
Wallace, E., Dillon, C., Dimitrov, B. D., Fahey, T. P., & Keogh, C. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-02-0061 · Cited by 122
Chao, T., Lip, G. Y. H., Liu, C., Tuan, T., Chen, S., Wang, K.-L., Lin, Y., Chang, S., Lo, L., Hu, Y., et al. (2016) · Stroke · doi:10.1161/strokeaha.116.013880 · Cited by 119
Self-citationLip, G. Y. H., & Lane, D. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13386 · Cited by 117
Self-citationBanerjee, A., Taillandier, S., Olesen, J. B., Lane, D. A., Lallemand, B., Lip, G. Y. H., & Fauchier, L. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs005 · Cited by 109
Self-citationSkjøth, F., Nielsen, P., Larsen, T. B., & Lip, G. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0565 · Cited by 106 · cited 2×
“Notwithstanding the fact that even one stroke risk factor confers an excess risk of stroke and death, and that OAC has a positive NCB with one or more stroke risk factors (25), the CHA2DS2-VASc score should be used in a stepwise approach to initially identify ‘low risk’ patients (Step 1), defined as a CHA2DS2-VASc sco…”
Self-citationCosta, F. M., Ferreira, J., Mendes, M., & Carmo, J. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0203 · Cited by 103
Hendriks, J., Tomini, F., van Asselt, T., Crijns, H., & Vrijhoef, H. (2013) · Europace · doi:10.1093/europace/eut055 · Cited by 100
Chai‐Adisaksopha, C., Hillis, C., Monréal, M., Witt, D. M., & Crowther, M. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0063 · Cited by 98
Dabigatran use in elderly patients with atrial fibrillation
Avgil-Tsadok, M., Jackevicius, C. A., Essebag, V., Eisenberg, M. J., Rahme, E., Behlouli, H., & Pilote, L. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0247 · Cited by 95
Emerging anticoagulant strategies
Fredenburgh, J. C., Gross, P. L., & Weitz, J. I. (2016) · Blood · doi:10.1182/blood-2016-09-692996 · Cited by 84
Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation
Ambrosino, P., Russo, A. D., Casella, M., Tremoli, E., Tondo, C., & Minno, M. N. D. D. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0532 · Cited by 77
Fauchier, L., Clémenty, N., Bisson, A., Ivanés, F., Angoulvant, D., Babuty, D., & Lip, G. Y. H. (2016) · Stroke · doi:10.1161/strokeaha.116.013253 · Cited by 76
Self-citationRuff, C. T., Giugliano, R. P., Braunwald, E., Murphy, S. A., Brown, K. S., Jarolím, P., Mercuri, M. F., Antman, E. M., & Morrow, D. A. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3311 · Cited by 76
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
Pollack, C. V., & Weitz, J. I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0222 · Cited by 70
Freedman, B., Gersh, B. J., & Lip, G. Y. H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu494 · Cited by 70
Self-citationTiming of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation
Paciaroni, M., Agnelli, G., Ageno, W., & Caso, V. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0217 · Cited by 62
Bertoméu, V., Cequier, A. R., Marín, F. R., Anguita, M. P., & Ortiz, M. R. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0169 · Cited by 61
Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
Olesen, J. B., & Torp-Pedersen, C. T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0154 · Cited by 59
Siegbahn, A., Oldgren, J., Andersson, U., Ezekowitz, M. D., Reilly, P. A., Connolly, S. J., Yusuf, S., Wallentin, L. C., & Eikelboom, J. W. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0529 · Cited by 58
Proietti, M., Senoo, K., Lane, D. A., & Lip, G. Y. H. (2016) · Scientific Reports · doi:10.1038/srep24376 · Cited by 56
Self-citationAgnelli, G., & Paciaroni, M. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-08-0667 · Cited by 52 · cited 4×
“For example, the independent FDA Medicare analysis by Graham et al. (61) reported that treatment with rivaroxaban 20 mg once daily was associated with similar risks of thromboembolic stroke but statistically significant increases in ICH and major extracranial bleeding, including major gastrointestinal bleeding, compar…”
BackgroundInfluentialHsu, J. C., Chan, P. S.-F., Tang, F., Maddox, T. M., & Marcus, G. M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.11.035 · Cited by 52
The risks of risk scores for stroke risk assessment in atrial fibrillation
Chao, T., & Nielsen, P. B. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0210 · Cited by 50
Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke
Freedman, B., & Lowres, N. (2015) · JAMA · doi:10.1001/jama.2015.9846 · Cited by 47
Self-citationPhilippart, R., Brunet-Bernard, A., Clémenty, N., Bourguignon, T., Mirza, A., Angoulvant, D., Babuty, D., Lip, G. Y. H., & Fauchier, L. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0007 · Cited by 45
Self-citationLip, G. Y. H., & Nielsen, P. B. (2016) · Circulation · doi:10.1161/circulationaha.115.016713 · Cited by 44
Self-citationManaging reversal of direct oral anticoagulants in emergency situations
Buller, H. R., Falanga, A., Hacke, W., Hendriks, J., Lobban, T., Merino, J. L., Milojević, I., Moya, F., van der Worp, H. B., Randall, G., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0363 · Cited by 43
Renda, G., Nicola, M. D., & Caterina, R. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.03.034 · Cited by 40
Bernaitis, N., Ching, C. K., Chen, L., Hon, J. S., Teo, S. C., Davey, A. K., & Anoopkumar‐Dukie, S. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.08.030 · Cited by 40
Ankle-Brachial Index and cardiovascular events in atrial fibrillation: The ARAPACIS Study
Davi, G., Proietti, M., Pastori, D., Hiatt, W. R., Corazza, G. R., Perticone, F., Pignatelli, P., Farcomeni, A., Vestri, A. R., Lip, G. Y. H., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0612 · Cited by 37
Self-citationWang, H., Tian, Y., Guo, Y., Wang, Y., & Lip, G. Y. H. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0577 · Cited by 33
Self-citationHung, Y., Chao, T., Liu, C., Tuan, T., Lin, Y., Chang, S., Lo, L., Hu, Y., Liao, J., Chung, F., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003839 · Cited by 22
Self-citationClinical impact and course of major bleeding with edoxaban versus vitamin K antagonists
Brekelmans, M. P. A., Bleker, S. M., Bauersachs, R. M., Boda, Z., Buller, H. R., Choi, Y., Gallus, A. S., GROSSO, M. A., Middeldorp, S., Oh, D., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-11-0892 · Cited by 18
Operationalizing the 2014 ACC/AHA Guidelines for Valvular Heart Disease
Nishimura, R. A., & Carabello, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.065 · Cited by 18
Dabigatran in Patients with Mechanical Heart Valves
Eikelboom, J. W., Brueckmann, M., & de Werf, F. V. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1315004 · Cited by 17
Adding Rigor to Stroke Rate Investigations in Patients With Atrial Fibrillation
Nielsen, P. B., & Lip, G. Y. H. (2017) · Circulation · doi:10.1161/circulationaha.116.025944 · Cited by 14
Self-citationParakramawansha, R., Quinn, T. J., Tait, R. C., & Wilson, M. R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0025 · Cited by 10
Blann, A. D., Boriani, G., & Lip, G. Y. H. (2016) · EP Europace · doi:10.1093/europace/euw211 · Cited by 10
Self-citationDarwiche, W., Bejan‐Angoulvant, T., Angoulvant, D., Babuty, D., & Fauchier, L. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0483 · Cited by 9
Cited by
Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge
Lippi, G., Sanchis-Gomar, F., & Cervellin, G. (2021) · International Journal of Stroke · doi:10.1177/1747493019897870 · Cited by 1,437
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Self-citationThe ABC pathway: an integrated approach to improve AF management
Lip, G. Y. H. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.153 · Cited by 627
Self-citationMobile Photoplethysmographic Technology to Detect Atrial Fibrillation
Guo, Y., Wang, H., Zhang, H., Liu, T., Liang, Z., Xia, Y., Yan, L., Xing, Y., Shi, H., Li, S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.019 · Cited by 489
Self-citationLip, G. Y. H., Keshishian, A., Li, X., Hamilton, M., Masseria, C., Gupta, K., Luo, X., Mardekian, J., Friend, K., Nadkarni, A., et al. (2018) · Stroke · doi:10.1161/strokeaha.118.020232 · Cited by 323
Self-citation
Metadata
- Authors
- Lip, G. Y. H., Freedman, B., De Caterina, R., & Potpara, T. S.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2017
- Volume
- 117
- Issue
- 07
- Pages
- 1230-1239
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2623061081
- Cited by
- 400
- References
- 91
- FWCI
- 48.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.